|
TPMT expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.63358215843346E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.03048688973695E-12 |
| Normal-vs-Stage2 |
1.657150E-03 |
| Normal-vs-Stage3 |
1.62714286489063E-12 |
| Normal-vs-Stage4 |
1.62436730732907E-12 |
| Stage1-vs-Stage2 |
4.287700E-02 |
| Stage1-vs-Stage3 |
4.513800E-02 |
| Stage1-vs-Stage4 |
1.248620E-04 |
| Stage2-vs-Stage3 |
1.843330E-03 |
| Stage2-vs-Stage4 |
7.75460000000949E-05 |
| Stage3-vs-Stage4 |
7.588200E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62458935193399E-12 |
| Normal-vs-AfricanAmerican |
3.484300E-03 |
| Normal-vs-Asian |
2.13185025188523E-12 |
| Caucasian-vs-AfricanAmerican |
1.273360E-01 |
| Caucasian-vs-Asian |
8.385400E-01 |
| AfricanAmerican-vs-Asian |
2.126600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.51567647321826E-12 |
| Normal-vs-Female |
1.63968838506889E-12 |
| Male-vs-Female |
8.561000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.89215310086865E-12 |
| Normal-vs-Age(41-60Yrs) |
3.56048523997288E-13 |
| Normal-vs-Age(61-80Yrs) |
1.30673249998381E-12 |
| Normal-vs-Age(81-100Yrs) |
3.119700E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.284000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.176600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.981400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.870000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.483600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.413400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.44699999654807E-08 |
| Classical-VS-Follicular |
5.09190467568033E-11 |
| Classical-VS-Other |
7.988200E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
1.62436730732907E-12 |
| Tall-VS-Other |
1.411870E-02 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
8.436400E-04 |
| Follicular-VS-Normal |
1.156010E-01 |
| Other-VS-Normal |
4.12100000000137E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.15789999810545E-09 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
5.54079999992574E-07 |
|
|
